Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
Rhea-AI Summary
Abpro Holdings (Nasdaq: ABP) has announced an upcoming oral presentation of preclinical data for their drug candidate ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-Cell Engager, at the AACR Annual Meeting 2025. The presentation will take place during the New Drugs on the Horizon session at McCormick Place Convention Center in Chicago, between April 25-30.
The company, which focuses on developing next-generation antibody therapies for severe and life-threatening diseases, has established a strategic partnership with Celltrion for the worldwide development and commercialization of ABP-102/CT-P72.
Positive
- Strategic partnership with Celltrion for worldwide development and commercialization
- Selection for oral presentation at major cancer research conference (AACR 2025)
- First preclinical data to be presented for novel T-cell engager technology
Negative
- Drug candidate still in early preclinical stage, far from potential commercialization
News Market Reaction 1 Alert
On the day this news was published, ABP declined 4.63%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Abpro has a strategic partnership with Celltrion for worldwide development and commercialization of AB-102/CT-P72
WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102/CT-P72 at the American Association for Cancer ResearchⓇ Annual Meeting 2025 (“AACR 2025”) in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago.
Invited speaker presentation details
| Title: | ABP-102/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with normal HER2 expression levels |
| Session: | New Drugs on the Horizon: Part 1 |
| Session Date: | Sunday, April 27, 2025 |
| Session Time: | 1:00 pm to 2:30 pm CDT |
| Presenter: | Adam J. Pelzek, Ph.D., Associate Director, Abpro |
| Abstract & Data: | Embargoed until time of presentation |
About ABP-102/CT-P72
ABP-102/CT-P72 an investigational HER2 x CD3 bispecific T-cell engager designed using Abpro’s proprietary DiversImmune® platform to selectively target HER2-overexpressing tumor cells while reducing activity in HER2-low expressing normal tissues. Its tetravalent IgG1-[L]-scFv format enables bivalent HER2 binding with functionally monovalent CD3 engagement and is designed to optimize tumor selectivity and reduce cytokine-related toxicity. Abpro has an exclusive collaboration with Celltrion, a leading South Korean biotechnology company ranked among the world’s top 25 by market capitalization, to advance ABP-102/CT-P72 in development for the treatment of HER2+ breast, gastric, pancreatic, colorectal, and other cancers.
About Abpro
Abpro’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+ cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using Abpro's proprietary DiversImmune® platform. Abpro is located in Woburn, Massachusetts. For more information, please visit www.abpro.co.
Abpro Contacts Company: info@abpro.co Investors: ir@abpro.co Media: pr@abpro.co
FAQ
What is ABP-102/CT-P72 and how does it work?
When will Abpro (ABP) present the preclinical data for ABP-102/CT-P72?
Who is partnering with Abpro (ABP) for ABP-102/CT-P72 development?
What stage of development is ABP-102/CT-P72 currently in?
